02 April 2024
ImmuPharma PLC
("ImmuPharma" or the "Company")
New intellectual property strategy initiated
to significantly enhance patent life and commercial value for P140 technology platform
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that it has initiated a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.
P140 is ImmuPharma's technology platform for its portfolio in autoimmune diseases. This comprises the lead indication commencing a Phase 3 clinical study in systemic lupus erythematosus ("SLE") and the second indication, in preparation for a Phase 2/3 adaptive clinical study in chronic idiopathic demyelinating polyneuropathy ("CIDP").
New insights into the P140 technology lends itself to expanding the current patent portfolio. This new patent initiative will strengthen the commercial value of P140 and add to the positive engagement we are already experiencing in discussions with a broad range of potential commercial partners on SLE and CIDP.
New patents will not only significantly enhance the patent protection for P140 in SLE and CIDP but will also support patient studies in other auto-immune/inflammatory diseases and release further value from the P140 technology platform.
Commenting on the announcement, Tim McCarthy, CEO of ImmuPharma, said:
"This is an important new initiative which will greatly improve the intellectual property protection for our P140 technology platform and extend its patent life significantly. This in turn creates greater shareholder value and it is particularly pertinent as we progress discussions with a broad range of potential commercial partners on both the SLE and CIDP programs."
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
| For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.
About Lupus (Systemic Lupus Erythematosus / SLE)
Lupus is a chronic inflammatory disease which is thought to affect some 16 million individuals worldwide. The current standard of care still consists of steroid and anti-malarial therapies which many have side-effects and poor response in many patients. Recently more targeted monoclonal therapies are GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There still exists a high unmet medical need for a drug that has a strong efficacy and safety profile.
About CIDP (Chronic Idiopathic Demyelinating Polyneuropathy)
CIDP is a rare acquired autoimmune disorder of peripheral nerves which is thought to affect some 90,000individuals across US/Europe. It is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. CIDP related disability may be substantial. In addition to the physical burdens imposed by the disease, those affected by CIDP also frequently experience economic and emotional hardship and are often burdened not only by the disease but also by the immunotherapies used to treat the disease. Other than intravenous (IVIG) and subcutaneous immunoglobulin (SCIG), corticosteroids and plasma exchange are the only other treatment options. There is still a huge unmet need for more efficacious drugs that are safer, and which affect underlying disease progression.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.